Test a personalized maintenance plan for pemphigus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 to 80, and you (or a family member if you can’t) can give consent to join
- Your pemphigus is newly diagnosed and confirmed by specific skin or mouth test results (biopsy plus IgG/complement findings)
- Your disease is active enough to score above a required level on the PDAI (more active disease = higher score)
- You can take the standard treatments used in this study: prednisone by mouth plus rituximab
- You must be vaccinated for COVID-19 before starting (and flu/pneumonia vaccines are recommended, with a specific pneumococcal dose before entry)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
This study tests a new drug, CM313, for people with moderate to severe pemphigus (a blistering skin disease). It aims to see if the drug can help heal the blisters and sores.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This trial tests a new drug called CM313 for people with moderate to severe pemphigus, a blistering skin condition. It's for patients who haven't had this treatment before and may have not responded well to other therapies.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
This trial compares two treatment combinations for moderate-to-severe pemphigus: rituximab plus steroids versus steroids plus azathioprine. The goal is to find which approach controls the disease better while reducing side effects.
Hear when a new Pemphigus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.